Aniridia is a rare genetic disorder characterized by the partial or complete absence of the iris, the colored part of the eye. It is estimated that aniridia affects approximately 1 in 50,000 to 100,000 individuals worldwide, making it a relatively uncommon condition.
The prevalence of aniridia can vary among different populations and regions. Studies have shown that it occurs with slightly higher frequency in certain ethnic groups, such as the Finnish population, where the prevalence is estimated to be around 1 in 40,000 individuals.
Aniridia is typically present from birth and can lead to various visual impairments, including reduced visual acuity, sensitivity to light, and difficulties with depth perception. Additionally, individuals with aniridia may experience other eye abnormalities, such as cataracts, glaucoma, and corneal problems.
Due to its rarity, aniridia often requires specialized medical care and ongoing management to address the associated visual and ocular complications. Early diagnosis and intervention are crucial in optimizing visual outcomes and improving the quality of life for individuals living with aniridia.